Annual Meeting of the Society for Gynecologic Oncologists
ORLANDO — Researchers have found that miR-378 may
be associated with treatment response after chemotherapy with bevacizumab in
recurrent ovarian cancer.
“MicroRNA has been shown to regulate gene
expression, but more specifically in ovarian cancer it has been shown to impact
survival and also predict response to chemotherapy in ovarian cancer, as well
as in pancreatic, lung, breast, prostate and colorectal malignancies,”
according to John Chan, MD, of the University of California, San
Francisco Helen Diller Family Comprehensive Cancer Center, who presented
findings of the study. “However, there is no information of its ability to
predict response to biologic agents like bevacizumab.”
Data on demographics, clinicopathology, survival and
genomics were extracted from The Cancer Genome Atlas. All patients had
recurrent ovarian cancer and were treated with chemotherapy plus
bevacizumab (Avastin, Genentech/Roche). Al of the patients
had serous histology and had undergone primary surgery. The median time to
recurrence was 11.3 months and the 5-year OS was 51%.
The most common chemotherapy regimens used included
cyclophosphamide, doxorubicin and platinum-taxane combination, each with
bevacizumab. The median time to recurrence after treatment was 3.34 months.
Patients who had a treatment-free interval of greater than 3 months had a
5-year OS of 78.3% vs. 16.7% for patients who had a shorter treatment-free
The researchers found that upregulation of miR-128 and
miR-375, as well as downregulation of miR-214, miR-145, miR-21, miR-378 and
miR-375 were associated with longer PFS after treatment with chemotherapy and
bevacizumab. The six-month PFS after treatment with chemotherapy and
bevacizumab was 77.8% in patients who had downregulation of miR-378, compared
with 33.6% in
patients who had normal miR-378.
On multivariate analysis, treatment-free interval and
miR-378 expression remained as independent predictors of response to treatment
with chemotherapy and bevacizumab.
Disclosures: The researchers report no
For more information:
- Chan J. #6. 42nd Annual Meeting of the Society for
Gynecologic Oncologists. March 6-9, 2011. Orlando, Fla.